

ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or the "Company")

Update on Private Placement and Placing

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company, announces an update to its Private Placement announced on 24 September 2024 and the Fundraising announced on 1 November 2024.

The settlement of the Private Placement with a Canadian private investor has been delayed due to their unavoidable personal circumstances and will require additional time to complete. In light of this, settlement of the Fundraising scheduled for Nov 11 will also be delayed coinciding with the Private Placement settlement. Further updates will be provided in due course.

-Ends-

Enquiries:

Ondine Biomedical Inc.

Angelika Vance, Vice President of Corporate Communications

+001 604 838 2702

Singer Capital Markets (Nominated Adviser, Joint Broker)

Phil Davies, Sam Butcher

+44 (0)20 7496 3000

RBC Capital Markets (Joint Broker)

Rupert Walford, Kathryn Deegan

+44 (0)20 7653 4000

Vane Percy & Roberts (Media Contact for Ondine Biomedical)

Simon Vane Percy, Amanda Bernard

+44 (0)77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader innovating light-activated antimicrobial therapies (also known as 'photodisinfection'). In addition to Steriwave, Ondine has a pipeline of products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDKZMMMVMKGDZG